ABBV vs KO Comparison: AI Score, Valuation, Performance and Upside
ABBV holds the edge across 4 of 5 key metrics in this comparison. ABBV leads on both 1-year return (+25.34%) and forward P/E quality (15.45x vs 24.84x for KO), a relatively favorable combination of momentum and valuation. ABBV leads on both revenue growth (10.20%) and operating margin (39.57%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +7.75% for ABBV and +8.11% for KO.
| Metric | ABBV | KO |
|---|---|---|
| AI score | 52.7 | 50.8 |
| AI rank | #328 | #424 |
| Latest close | $246.04 | $87.05 |
| 1M return | -2.65% | +4.38% |
| 6M return | +12.34% | +10.88% |
| 1Y return | +25.34% | +25.23% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | KO |
|---|---|---|
| 1Y ago | $12.37K (+23.7%) started 2025-08-07 | $12.36K (+23.6%) started 2025-08-07 |
| 5Y ago | $29.1K (+191.0%) started 2021-08-09 | $19.38K (+93.8%) started 2021-08-09 |
| 10Y ago | $84.05K (+740.5%) started 2016-08-08 | $36.34K (+263.4%) started 2016-08-08 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | KO |
|---|---|---|
| Market cap | $443.36B | $376.86B |
| Trailing P/E | 70.89 | 26.30 |
| Forward P/E | 15.45 | 24.84 |
| Price/Sales | 5.85 | 6.55 |
| EV/Revenue | 7.87 | 8.12 |
| Analyst target | $270.39 | $94.70 |
| Target upside | +7.75% | +8.11% |
| Metric | ABBV | KO |
|---|---|---|
| Revenue growth | 10.20% | 6.70% |
| Earnings growth | 290.40% | 16.90% |
| EPS growth | +290.40% | +16.90% |
| FCF margin | +32.32% | +10.41% |
| Operating margin | 39.57% | 34.89% |
| Profit margin | 9.80% | 28.56% |
| ROIC proxy | 6225.00% | 42.05% |
| Return on equity | 6225.00% | 42.05% |
| Dividend yield | 2.76% | 2.42% |
| Beta | 0.28 | 0.35 |
| Debt/equity | 4789.60 | 115.52 |
| Current ratio | 0.80 | 1.30 |
| Quick ratio | 0.52 | 0.80 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | KO |
|---|---|---|---|
| 1Y | Growth | +23.73% | +23.60% |
| CAGR | +23.76% | +23.64% | |
| Sharpe ratio | 0.78 | 0.99 | |
| Max drawdown | 19.23% | 8.50% | |
| Max daily drop | 5.20% | 3.96% | |
| Max wkly drop | 8.49% | 5.54% | |
| 5Y | Growth | +149.21% | +72.03% |
| CAGR | +20.06% | +11.47% | |
| Sharpe ratio | 0.71 | 0.47 | |
| Max drawdown | 21.92% | 17.27% | |
| Max daily drop | 12.57% | 6.96% | |
| Max wkly drop | 17.30% | 7.43% | |
| 10Y | Growth | +437.62% | +164.39% |
| CAGR | +18.32% | +10.21% | |
| Sharpe ratio | 0.61 | 0.38 | |
| Max drawdown | 45.09% | 36.99% | |
| Max daily drop | 16.25% | 9.67% | |
| Max wkly drop | 19.39% | 20.98% |
| Category | ABBV | KO |
|---|---|---|
| Company | ABBV | KO |
| Sector | Healthcare | Consumer Defensive |
| Industry | Drug Manufacturers - General | Beverages - Non-Alcoholic |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.